德拉马尼治疗耐多药结核病的研究进展  

Research Progress on Delamanid in the Treatment of Multi-drug Resistant Tuberculosis

作　　者：张珊珊 陈玲 ZHANG Shanshan;CHEN Ling(Tuberculosis Ward,Department of Pulmonary and Critical Care Medicine,the Affiliated Hospital of Zunyi Medical University,Zunyi 563003,China)

机构地区：[1]遵义医科大学附属医院呼吸与危重症医学科结核病区

出　　处：《实用心脑肺血管病杂志》2019年第12期17-20,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：国家自然科学基金资助项目(81760003)

摘　　要：耐多药结核病(MDR-TB)仍是目前全球公共卫生危机和卫生安全威胁之一,而我国是MDR-TB高负担国家之一。德拉马尼作为一种新型抗结核药物,主要通过抑制结核分枝杆菌细胞壁分枝菌酸合成而发挥杀菌作用,并有望缩短MDR-TB治疗疗程,已引起临床关注和重视。本文主要综述了德拉马尼的作用机制及抗菌活性、临床前研究及临床试验、毒副作用及药物-药物相互作用、耐药机制等,以提高临床对德拉马尼的认识并为合理应用该药提供参考。Multi-drug resistant tuberculosis(MDR-TB)is one of global public health crises and threats to health security,however China is one of the countries with high burden of MDR-TB. As a new anti-tuberculosis drug,delamanid plays an antibacterial role by inhibiting the synthesis of mycolic acid in cell wall of Mycobacterium tuberculosis,which is expected to shorten the course of treatment of MDR-TB and has attracted clinical attention. This paper mainly reviewed the action mechanism and antibacterial activity,preclinical studies and clinical trials,toxic side effects and drug-drug interaction,resistance mechanism of delamanid,to improve the clinical understanding and rational usage level of delamanid.

关 键 词：结核 结核分枝杆菌 广泛耐药结核 德拉马尼 突变 综述 

分 类 号：R63[医药卫生—外科学]